Latest News

Symptom-based dosing reduced time to medical readiness for discharge compared with scheduled opioid, without increasing short-term safety risks.

Pharmacy learner–led opioid overdose and naloxone training significantly improved community preparedness and confidence in responding to opioid overdoses.

Pharmacists play a crucial role in the treatment of patients with chronic myeloid leukemia (CML) taking tyrosine kinase inhibitors.

The approval follows positive results from a phase 3 randomized withdrawal trial.

CAR T drives deep remissions in myeloma and lymphoma, but payers, staffing, and hospital partners shape timely community access.

NABP’s new uniform pharmacy law exam streamlines multistate licensure, reshapes MPJE prep, and speeds pharmacist mobility in 2026.

At AXS2026, pharmacy and health care leaders explored how AI is transforming specialty care and why standards, trust, and oversight must keep pace with innovation.

2026 dyslipidemia guideline updates highlight earlier risk-based lipid management, expanded biomarker use, and a growing pharmacist role in cardiovascular prevention.

The rare disease space is an area where scientific rigor meets genuine human impact.

Cannabis use is common among patients receiving medications for opioid use disorder and is associated with higher rates of anxiety and other comorbid symptoms.

Oncology pharmacists should weigh lung cancer and diet data, probing pesticides as a possible factor in young nonsmokers.

The FDA expands teplizumab-mzwv use to ages 1+ with stage 2 type 1 diabetes, detailing PETITE-T1D safety, EBV/CMV precautions, and pharmacist support to delay onset.

Two studies presented at the World Congress of Nephrology 2026 highlight nonpharmacological strategies that may help preserve kidney function in at-risk populations.

Pharmacists drive acne management by choosing proven OTC ingredients, coaching skin care routines, debunking trends, and knowing when to refer patients to specialists.

The once-weekly Saphnelo Pen offers adult patients with systemic lupus erythematosus a new, at-home alternative to monthly intravenous infusions, supported by robust phase 3 data.

The emerging data suggest a potential adjunctive strategy to target microbial drivers of head and neck squamous cell carcinoma.

Large real-world analysis supports potential renal and survival benefits of urate-lowering therapy in patients with chronic kidney disease and hyperuricemia.

The actions will support the development of psychedelic-based therapies for PTSD, depressive disorders, and substance use disorders.

Sports Pharmacy Summit unites global experts on anti-doping, supplement safety, and data-driven performance to protect athlete health.

The reclassification of medical marijuana to Schedule III marks a major policy shift that expands research and introduces new potential health care challenges.